文献速递类风湿关节炎

托珠单抗与其他生物制剂治疗类风湿关节炎的严重感染风险:多数据库队列研究

Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
PubMed 文献 · Ann Rheum Dis · 2019-01-24

该研究利用美国Medicare、IMS与MarketScan数据库,纳入既往使用过至少一种其他生物制剂或托法替布的类风湿关节炎患者,比较托珠单抗(TCZ)与TNF抑制剂(TNFi)或阿巴西普启动者的严重感染风险。结果显示TCZ与TNFi的复合严重感染风险无差异,但TCZ的严重细菌感染、皮肤软组织感染及憩室炎风险更高;TCZ较阿巴西普复合严重感染风险更高。

要点

  • TCZ与TNFi复合严重感染风险无差异(合并HR 1.05,95%CI 0.95至1.16)。
  • TCZ较TNFi严重细菌感染、皮肤软组织感染及憩室炎风险升高。
  • TCZ较阿巴西普复合严重感染及多种特定感染风险升高。

核心结论

  • 在既往至少一种生物制剂或托法替布治疗失败的RA患者中,启动TCZ与TNFi的复合严重感染风险无差异。
  • TCZ较TNFi的严重细菌感染、皮肤软组织感染和憩室炎风险更高。
  • TCZ较阿巴西普的复合严重感染风险更高。

研究设计与样本

  • 基于美国Medicare(2010–2015年)、IMS与MarketScan(2011–2015年)理赔数据的多数据库队列研究。
  • 纳入启动TCZ或TNFi(主要对照)/阿巴西普(次要对照)且既往使用≥1种不同生物制剂或托法替布的成年RA患者。
  • 主要结局为住院严重感染(SI),包括细菌、病毒或机会性感染;采用倾向评分匹配控制>70个混杂因素,数据库特异性HR经荟萃分析合并。

主要发现

  • 主要队列含16 074例TCZ倾向评分匹配者与33 109例TNFi启动者。
  • TCZ与TNFi复合SI风险无差异(合并HR 1.05,95%CI 0.95至1.16)。
  • TCZ较TNFi严重细菌感染HR 1.19(95%CI 1.07至1.33)、皮肤软组织感染HR 2.38(95%CI 1.47至3.86)、憩室炎HR 2.34(95%CI 1.64至3.34)。
  • TCZ较阿巴西普复合SI、严重细菌感染、憩室炎、肺炎/上呼吸道感染及败血症/菌血症风险升高。

关键数值与推荐

  • 复合严重感染:TCZ vs TNFi合并HR 1.05(95%CI 0.95至1.16)。
  • 严重细菌感染:TCZ vs TNFi HR 1.19(95%CI 1.07至1.33)。
  • 皮肤软组织感染:TCZ vs TNFi HR 2.38(95%CI 1.47至3.86)。
  • 憩室炎:TCZ vs TNFi HR 2.34(95%CI 1.64至3.34)。

临床怎么用

  • 对既往生物制剂或托法替布失败的RA患者,选择TCZ时需权衡严重细菌感染、皮肤软组织感染及憩室炎风险。
  • 有相关感染或憩室炎风险因素者,可考虑TNFi或阿巴西普等替代方案。

局限性

  • 为观察性理赔数据研究,可能存在残余混杂。
  • 结论基于特定数据库与人群,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the rate of serious bacterial, viral or opportunistic infection in patients with rheumatoid arthritis (RA) starting tocilizumab (TCZ) versus tumour necrosis factor inhibitors (TNFi) or abatacept. METHODS: Using claims data from US Medicare from 2010 to 2015, and IMS and MarketScan from 2011 to 2015, we identified adults with RA who initiated TCZ or TNFi (primary comparator)/abatacept (secondary comparator) with prior use of ≥1 different biologic drug or tofacitinib. The primary outcome was hospitalised serious infection (SI), including bacterial, viral or opportunistic infection. To control for >70 confounders, TCZ initiators were propensity score (PS)-matched to TNFi or abatacept initiators. Database-specific HRs were combined by a meta-analysis. RESULTS: The primary cohort included 16 074 TCZ PS-matched to 33 109 TNFi initiators. The risk of composite SI was not different between TCZ and TNFi initiators (combined HR 1.05, 95% CI 0.95 to 1.16). However, TCZ was associated with an increased risk of serious bacterial infection (HR 1.19, 95% CI 1.07 to 1.33), skin and soft tissue infections (HR 2.38, 95% CI 1.47 to 3.86), and diverticulitis (HR 2.34, 95% CI 1.64 to 3.34) versus TNFi. An increased risk of composite SI, serious bacterial infection, diverticulitis, pneumonia/upper respiratory tract infection and septicaemia/bacteraemia was observed in TCZ versus abatacept users. CONCLUSIONS: This large multidatabase cohort study found no difference in composite SI risk in patients with RA initiating TCZ versus TNFi after failing ≥1 biologic drug or tofacitinib. However, the risk of serious bacterial infection, skin and soft tissue infections, and diverticulitis was higher in TCZ versus TNFi initiators. The risk of composite SI was higher in TCZ initiators versus abatacept.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Pawar A, Desai RJ, Solomon DH, et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019. PMID: 30679153. doi:10.1136/annrheumdis-2018-214367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。